Identification of DNA methylation biomarkers with potential to predict response to neoadjuvant chemotherapy in triple-negative breast cancer
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1868-7083
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Identification of DNA methylation biomarkers with potential to predict response to neoadjuvant chemotherapy in triple-negative breast cancer ; volume:13 ; number:1 ; day:18 ; month:12 ; year:2021 ; pages:1-7 ; date:12.2021
Clinical epigenetics ; 13, Heft 1 (18.12.2021), 1-7, 12.2021
- Urheber
-
Meyer, Braydon
Clifton, Samuel
Locke, Warwick
Luu, Phuc-Loi
Du, Qian
Lam, Dilys
Armstrong, Nicola J.
Kumar, Beena
Deng, Niantao
Harvey, Kate
Swarbrick, Alex
Ganju, Vinod
Clark, Susan J.
Pidsley, Ruth
Stirzaker, Clare
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s13148-021-01210-6
- URN
-
urn:nbn:de:101:1-2022041320100507745975
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:25 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Meyer, Braydon
- Clifton, Samuel
- Locke, Warwick
- Luu, Phuc-Loi
- Du, Qian
- Lam, Dilys
- Armstrong, Nicola J.
- Kumar, Beena
- Deng, Niantao
- Harvey, Kate
- Swarbrick, Alex
- Ganju, Vinod
- Clark, Susan J.
- Pidsley, Ruth
- Stirzaker, Clare
- SpringerLink (Online service)
Ähnliche Objekte (12)
Evaluation of neoadjuvant chemotherapy for clinical T1 triple-negative breast cancer
Notch-based gene signature for predicting the response to neoadjuvant chemotherapy in triple-negative breast cancer
Outcomes of Triple-Negative Breast Cancer Patients in Response to Taxane and Nontaxane-Based Neoadjuvant Chemotherapies
Correction to: Co‑clinical FDG‑PET radiomic signature in predicting response to neoadjuvant chemotherapy in triple‑negative breast cancer
Predictive value of tumor-infiltrating lymphocytes to pathological complete response in neoadjuvant treated triple-negative breast cancers
Co-clinical FDG-PET radiomic signature in predicting response to neoadjuvant chemotherapy in triple-negative breast cancer
A Minimal lncRNA-mRNA Signature Predicts Sensitivity to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer
The PARTNER trial of neoadjuvant olaparib with chemotherapy in triple-negative breast cancer
The Immunomodulatory Effects of Dexamethasone on Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer
Escalation of neoadjuvant therapy in triple-negative breast cancer—balancing effectiveness and toxicities
Prediction of early clinical response to neoadjuvant chemotherapy in Triple-negative breast cancer: Incorporating Radiomics through breast MRI
A two-gene epigenetic signature for the prediction of response to neoadjuvant chemotherapy in triple-negative breast cancer patients
Evaluation of neoadjuvant chemotherapy for clinical T1 triple-negative breast cancer
Notch-based gene signature for predicting the response to neoadjuvant chemotherapy in triple-negative breast cancer
Outcomes of Triple-Negative Breast Cancer Patients in Response to Taxane and Nontaxane-Based Neoadjuvant Chemotherapies
Correction to: Co‑clinical FDG‑PET radiomic signature in predicting response to neoadjuvant chemotherapy in triple‑negative breast cancer
Predictive value of tumor-infiltrating lymphocytes to pathological complete response in neoadjuvant treated triple-negative breast cancers
Co-clinical FDG-PET radiomic signature in predicting response to neoadjuvant chemotherapy in triple-negative breast cancer
A Minimal lncRNA-mRNA Signature Predicts Sensitivity to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer
The PARTNER trial of neoadjuvant olaparib with chemotherapy in triple-negative breast cancer
The Immunomodulatory Effects of Dexamethasone on Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer
Escalation of neoadjuvant therapy in triple-negative breast cancer—balancing effectiveness and toxicities
Prediction of early clinical response to neoadjuvant chemotherapy in Triple-negative breast cancer: Incorporating Radiomics through breast MRI
A two-gene epigenetic signature for the prediction of response to neoadjuvant chemotherapy in triple-negative breast cancer patients
Evaluation of neoadjuvant chemotherapy for clinical T1 triple-negative breast cancer
Notch-based gene signature for predicting the response to neoadjuvant chemotherapy in triple-negative breast cancer
Outcomes of Triple-Negative Breast Cancer Patients in Response to Taxane and Nontaxane-Based Neoadjuvant Chemotherapies
Correction to: Co‑clinical FDG‑PET radiomic signature in predicting response to neoadjuvant chemotherapy in triple‑negative breast cancer
Predictive value of tumor-infiltrating lymphocytes to pathological complete response in neoadjuvant treated triple-negative breast cancers
Co-clinical FDG-PET radiomic signature in predicting response to neoadjuvant chemotherapy in triple-negative breast cancer
A Minimal lncRNA-mRNA Signature Predicts Sensitivity to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer
The PARTNER trial of neoadjuvant olaparib with chemotherapy in triple-negative breast cancer
The Immunomodulatory Effects of Dexamethasone on Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer
Escalation of neoadjuvant therapy in triple-negative breast cancer—balancing effectiveness and toxicities
Prediction of early clinical response to neoadjuvant chemotherapy in Triple-negative breast cancer: Incorporating Radiomics through breast MRI